Andra Chincisan

Andra Chincisan

Auto-generated profile, based on publicly available information

Andra Chincisan

Institute of Neuropathology

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
DHDaniel Heinzer
Daniel Heinzer
MAMerve Avar
Merve Avar
DPDaniel Patrick Pease
Daniel Patrick Pease
ADAshutosh Dhingra
Ashutosh Dhingra
JYJiang-An Yin
Jiang-An Yin
AAAdriano Aguzzi
Adriano Aguzzi
The cellular prion protein PrPC is necessary for prion replication, and its reduction greatly increases life expectancy in animal models of prion infection. Hence the factors controlling the levels of PrPC may represent therapeutic targets against human prion diseases. Here we performed an arrayed whole-transcriptome RNA interference screen to identify modulators of PrPC expression. We cultured human U251-MG glioblastoma cells in the presence of 64’752 unique siRNAs targeting 21’584 annotated human genes, and measured PrPC using a one-pot fluorescence-resonance energy transfer immunoassay in 51’128 individual microplate wells. This screen yielded 743 candidate regulators of PrPC. When downregulated, 563 of these candidates reduced and 180 enhanced PrPC expression. Recursive candidate attrition through multiple secondary screens yielded 54 novel regulators of PrPC, 9 of which were confirmed by CRISPR interference as robust regulators of PrPC biosynthesis and degradation. The phenotypes of 6 of the 9 candidates were inverted in response to transcriptional activation using CRISPRa. The RNA-binding post-transcriptional repressor Pumilio-1 was identified as a potent limiter of PrPC expression through the degradation of PRNP mRNA. Because of its hypothesis-free design, this comprehensive genetic-perturbation screen delivers an unbiased landscape of the genes regulating PrPC levels in cells, most of which were unanticipated, and some of which may be amenable to pharmacological targeting in the context of antiprion therapies.

11 January 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SSSilvia Sorce
Silvia Sorce
MNMario Nuvolone
Mario Nuvolone
GRGiancarlo Russo
Giancarlo Russo
ACAndra Chincisan
Andra Chincisan
DHDaniel Heinzer
Daniel Heinzer
AAAdriano Aguzzi
Adriano Aguzzi
The clinical course of prion diseases is accurately predictable despite long latency periods, suggesting that prion pathogenesis is driven by precisely timed molecular events. We constructed a searchable genome-wide atlas of mRNA abundance, splicing and editing alterations during the course of disease in prion-inoculated mice. Prion infection induced transient changes in mRNA abundance and processing already at eight weeks post inoculation, well ahead of any neuropathological and clinical signs. In contrast, microglia-enriched genes displayed an increase simultaneous with the appearance of clinical symptoms, whereas neuronal-enriched transcripts remained unchanged until the very terminal stage of disease. This suggests that glial pathophysiology, rather than neuronal demise, represents the final driver of disease. The administration of young plasma attenuated the occurrence of early mRNA abundance alterations and delayed symptoms in the terminal phase of the disease. The early onset of prion-induced molecular changes might thus point to novel biomarkers and potential interventional targets.

5 February 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAssunta Senatore
Assunta Senatore
KFKarl Frontzek
Karl Frontzek
MEMarc Emmenegger
Marc Emmenegger
ACAndra Chincisan
Andra Chincisan
MLMarco Losa
Marco Losa
AAAdriano Aguzzi
Adriano Aguzzi
Prion immunotherapy may hold great potential, but antibodies against certain PrP epitopes can be neurotoxic. Here we identified >6000 PrP-binding antibodies in a synthetic human Fab phage display library, 49 of which we characterized in detail. Antibodies directed against the flexible tail of PrP conferred neuroprotection against infectious prions. We then mined published repertoires of circulating B cells from healthy humans and found antibodies similar to the protective phage-derived antibodies. When expressed recombinantly, these antibodies exhibited anti-PrP reactivity. Furthermore, we surveyed 48’718 samples from 37’894 hospital patients for the presence of anti-PrP IgGs, and found 21 high-titer individuals. The clinical files of these individuals did not reveal any enrichment of specific pathologies, suggesting that anti-PrP autoimmunity is innocuous. The existence of protective anti-prion antibodies in unbiased human immunological repertoires, combined with the reported lack of such antibodies in carriers of disease-associated PRNP mutations, suggests a link to the low incidence of spontaneous prion diseases in human populations.

26 November 2021 in medRxiv
Verified
Preprint
Open access
PDF file
AMAndreia D. Magalhães
Andreia D. Magalhães
MEMarc Emmenegger
Marc Emmenegger
ECElena De Cecco
Elena De Cecco
MCManfredi Carta
Manfredi Carta
KFKarl Frontzek
Karl Frontzek
AAAdriano Aguzzi
Adriano Aguzzi
Intraneuronal aggregates of the microtubule-associated protein tau play a pivotal role in Alzheimer’s disease and several other neurodegenerative syndromes. Anti-tau antibodies can reduce pathology in mouse models of neurodegeneration and are currently tested in humans. Here, we performed a large-scale seroepidemiological search for anti-tau IgG autoantibodies (ατ) on 40,497 human plasma samples. High-titer ατ + individuals were surprisingly prevalent, with hospital patients being three times more likely to be ατ + (EC 50 ≥ 2 6 ; a nominal dilution of > 1/64) than healthy blood donors (4.8% vs 1.6%). The prevalence increased with age over 70 years-old (RR 1.26, 95%CI 1.11-1.43, P<0.001) and was higher for women (RR 1.20, 95%CI 1.07-1.39, P=0.002). The autoantibodies bound selectively to tau, inhibited tau aggregation in vitro , and interfered with tau detection in plasma samples. No association was found between ατ autoantibodies and neurological disorders. Instead, tau autoreactivity showed a significant association with kidney and urinary disorders (adjusted RR 1.27, 95%CI 1.10-1.45, P=0.001 and 1.40, 95%CI 1.20-1.63, P<0.001, respectively). These results suggest a previously unrecognized association between ατ autoimmunity and extraneural diseases.

28 January 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
DHDaniel Heinzer
Daniel Heinzer
MAMerve Avar
Merve Avar
DPDaniel Patrick Pease
Daniel Patrick Pease
ADAshutosh Dhingra
Ashutosh Dhingra
JYJiang-An Yin
Jiang-An Yin
AAAdriano Aguzzi
Adriano Aguzzi
The cellular prion protein PrP C is necessary for prion replication, and its reduction greatly increases life expectancy in animal models of prion infection. Hence the factors controlling the levels of PrP C may represent therapeutic targets against human prion diseases. Here we performed an arrayed whole-transcriptome RNA interference screen to identify modulators of PrP C expression. We cultured human U251-MG glioblastoma cells in the presence of 64’752 unique siRNAs targeting 21’584 annotated human genes, and measured PrP C using a one-pot fluorescence-resonance energy transfer immunoassay in 51’128 individual microplate wells. This screen yielded 743 candidate regulators of PrP C . When downregulated, 563 of these candidates reduced and 180 enhanced PrP C expression. Recursive candidate attrition through multiple secondary screens yielded 54 novel regulators of PrP C , 9 of which were confirmed by CRISPR interference as robust regulators of PrP C biosynthesis and degradation. The phenotypes of 6 of the 9 candidates were inverted in response to transcriptional activation using CRISPRa. The RNA-binding post-transcriptional repressor Pumilio-1 was identified as a potent limiter of PrP C expression through the degradation of PRNP mRNA. Because of its hypothesis-free design, this comprehensive genetic-perturbation screen delivers an unbiased landscape of the genes regulating PrP C levels in cells, most of which were unanticipated, and some of which may be amenable to pharmacological targeting in the context of antiprion therapies.

4 March 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
MAMerve Avar
Merve Avar
DHDaniel Heinzer
Daniel Heinzer
ATAlana M Thackray
Alana M Thackray
YLYingjun Liu
Yingjun Liu
MHMarian Hruska-Plochan
Marian Hruska-Plochan
AAAdriano Aguzzi
Adriano Aguzzi
A defining characteristic of mammalian prions is their capacity for self-sustained propagation. Theoretical considerations and experimental evidence suggest that prion propagation is modulated by cell-autonomous and non-autonomous modifiers. Using a novel quantitative phospholipase protection assay (QUIPPER) for high-throughput prion measurements, we performed an arrayed genome-wide RNA interference (RNAi) screen aimed at detecting modifiers of prion propagation. We exposed prion-infected cells in high-density microplates to 35’364 ternary pools of 52’746 siRNAs targeting 17’582 genes representing the mouse protein-coding transcriptome. We identified 1191 modulators of prion propagation. While 1151 of these modified the expression of both the pathological prion protein, PrP Sc , and its cellular counterpart PrP C , 40 genes affected selectively PrP Sc . Of the latter, 20 genes augmented prion production when suppressed. A prominent limiter of prion propagation was the heterogeneous nuclear ribonucleoprotein Hnrnpk. Psammaplysene A (PSA), which binds Hnrnpk, reduced prion levels in cultured cells and protected them from cytotoxicity. PSA also reduced prion levels in infected cerebellar organotypic slices and alleviated locomotor deficits in prion-infected Drosophila melanogaster expressing ovine PrP C . Hence, genome-wide QUIPPER-based perturbations can discover actionable cellular pathways involved in prion propagation. Finally, the unexpected identification of a prioncontrolling ribonucleoprotein suggests a role for RNA in the generation of infectious prions.